Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pulmonary Arterial Hypertension

ClinicalTrials.gov lists 691 trials for Pulmonary Arterial Hypertension or a narrower condition beneath it. Actelion has the most among industry and government lead sponsors, with 59.

MeSH D000081029 Respiratory Tract Diseases C08 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 75 Phase 1/2 Phase 1/2 14 Phase 2 Phase 2 116 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 104 Phase 4 Phase 4 63 Not applicable Not applicable 121 Observational Observational 183 Phase 1 Phase 1 75 Phase 1/2 Phase 1/2 14 Phase 2 Phase 2 116 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 104 Phase 4 Phase 4 63 Not applicable Not applicable 121 Observational Observational 183

Trials per phase (log scale)

1 more section with rows

691 of the 691 trials are tagged with Pulmonary Arterial Hypertension itself; the rest are tagged with a narrower condition beneath it.

Get the Pulmonary Arterial Hypertension report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pulmonary Arterial Hypertension trials start? (25)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 40

2002: 3 trials (Not applicable 1, Phase 4 1, Phase 2 1) 2003: 7 trials (Phase 4 2, Phase 3 5) 2004: 6 trials (Phase 4 1, Phase 3 4, Phase 2 1) 2005: 8 trials (Observational 2, Phase 4 2, Phase 3 3, Phase 2 1) 2006: 19 trials (Observational 2, Not applicable 2, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1 1) 2007: 17 trials (Observational 4, Not applicable 2, Phase 4 4, Phase 3 3, Phase 2 3, Phase 1 1) 2008: 25 trials (Observational 3, Not applicable 1, Phase 4 6, Phase 3 10, Phase 2/3 1, Phase 2 2, Phase 1 2) 2009: 18 trials (Observational 5, Not applicable 1, Phase 3 4, Phase 2 5, Phase 1 3) 2010: 40 trials (Observational 10, Not applicable 6, Phase 4 4, Phase 3 5, Phase 2 7, Phase 1/2 1, Phase 1 7) 2011: 40 trials (Observational 10, Not applicable 6, Phase 4 4, Phase 3 7, Phase 2 8, Phase 1/2 1, Phase 1 4) 2012: 31 trials (Observational 6, Not applicable 7, Phase 4 7, Phase 3 4, Phase 2 5, Phase 1/2 2) 2013: 36 trials (Observational 11, Not applicable 5, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 4, Phase 1 7) 2014: 23 trials (Observational 9, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 2) 2015: 30 trials (Observational 12, Not applicable 6, Phase 4 4, Phase 3 3, Phase 2 2, Phase 1 3) 2016: 26 trials (Observational 7, Not applicable 6, Phase 4 2, Phase 3 5, Phase 2 5, Phase 1 1) 2017: 37 trials (Observational 12, Not applicable 9, Phase 4 4, Phase 3 4, Phase 2 5, Phase 1 3) 2018: 38 trials (Observational 7, Not applicable 5, Phase 4 1, Phase 3 5, Phase 2 8, Phase 1/2 1, Phase 1 11) 2019: 40 trials (Observational 8, Not applicable 5, Phase 4 1, Phase 3 5, Phase 2 13, Phase 1/2 1, Phase 1 7) 2020: 20 trials (Observational 8, Not applicable 4, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 3) 2021: 39 trials (Observational 16, Not applicable 4, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 4, Phase 1 6) 2022: 28 trials (Observational 8, Not applicable 6, Phase 4 2, Phase 3 4, Phase 2 5, Phase 1 3) 2023: 37 trials (Observational 9, Not applicable 12, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 2) 2024: 31 trials (Observational 9, Not applicable 7, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 5) 2025: 31 trials (Observational 13, Not applicable 6, Phase 4 2, Phase 3 1, Phase 2 7, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 53
2025 31
2024 31
2023 37
2022 28
2021 39
2020 20
2019 40
2018 38
2017 37

Showing 10 of 25 earlier years.

Start your 14-day trial Email me all 25 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 61 trials starting in 2026 and about 43 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 51 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 441 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pulmonary Arterial Hypertension trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 75
Phase 1/2 14
Phase 2 116
Phase 2/3 9
Phase 3 104
Phase 4 63
Not applicable 121
Observational 183
Expanded access 6

How many Pulmonary Arterial Hypertension trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 41
Recruiting 78
Enrolling by invitation 4
Active, not recruiting 22
Available 1

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pulmonary Arterial Hypertension trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Actelion 59
United Therapeutics 44
Bayer 19
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 13
Bial - Portela C S.A. 12

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Pulmonary Arterial Hypertension? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Treprostinil 32
SILDENAFIL 26
BOSENTAN 21
Ambrisentan 18
ILOPROST 13

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Macitentan Dose 3 21
Sotatercept Autoinjector 17
Tadalafil Pill 13
Riociguat Pill 10
BIA 5-1058 9

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pulmonary Arterial Hypertension trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 646 66
Right ventricular failure 554 58
Pulmonary arterial hypertension 432 53
PULMONARY ARTERIAL HYPERTENSION 416 7
Pulmonary hypertension 381 35

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Pulmonary Arterial Hypertension? (138)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. Pediatric cardiology 2026 Yes
A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. The European respiratory journal 2025 Yes
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. The New England journal of medicine 2025 Yes
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS. Advances in therapy 2025 Yes
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study. Advances in therapy 2025 Yes

Showing 5 of 138 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (43)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Pulmonary arterial hypertension Point prevalence 1-9 / 100 000 United Kingdom GB Exact
Pulmonary arterial hypertension Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Pulmonary arterial hypertension Annual incidence 1-9 / 1 000 000 United Kingdom GB Unspecified
Pulmonary arterial hypertension Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Pulmonary arterial hypertension Point prevalence 1-9 / 100 000 United Kingdom GB Unspecified

Showing 5 of 43 prevalence observations.

Start your 14-day trial Email me all 43 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Pulmonary arterial hypertension 182090 Exact Orphadata Science knowledge files, Product 1
Pulmonary arterial hypertension 182090 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages